CA1173364A - Lecithin-hydrogen peroxide composition - Google Patents
Lecithin-hydrogen peroxide compositionInfo
- Publication number
- CA1173364A CA1173364A CA000394514A CA394514A CA1173364A CA 1173364 A CA1173364 A CA 1173364A CA 000394514 A CA000394514 A CA 000394514A CA 394514 A CA394514 A CA 394514A CA 1173364 A CA1173364 A CA 1173364A
- Authority
- CA
- Canada
- Prior art keywords
- lecithin
- hydrogen peroxide
- composition
- weight
- peroxide composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/22—Peroxides; Oxygen; Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Abstract
ABSTRACT OF THE DISCLOSURE
An antibacterial composition for the treatment of acne comprises a mixture of about 0.25-15% by weight lecithin and about 0.1-10% by weight hydrogen peroxide in a pharmaceutically acceptable solvent, based on the total weight of the composition.
An antibacterial composition for the treatment of acne comprises a mixture of about 0.25-15% by weight lecithin and about 0.1-10% by weight hydrogen peroxide in a pharmaceutically acceptable solvent, based on the total weight of the composition.
Description
~73~
BEB-18~28 ~lec D. Keith LECITHIN-HYDROGEN PEROXID~ COMPOSITION
This invention relates generally to compositions incorporating lecithin and hydrogen peroxide in an intimate admixture to provide a means to deliver topi-cal hydrogen peroxide in a stable form to a patient.
The compositions according to this invention find particular value in treating acne~
_C GROUND OF THE INVENTION
Hydrogen peroxide has long been known for its potent disinfectant activity. However, the benefits of this activity are counterweighted by the instability (and resulting short shelf life) of aqueous hydrogen -~ peroxide. When any hydrogen peroxide preparation is placed on the skin, the hydrogen peroxide is immediate-ly in danger of decomposition by enzyme processes such as by catalase, which is present in human tissues and in a wide variety of bacteria. Furthermore, applica-tions of aqueous hydrogen peroxide rapidly lose their effectiveness because they run off the skin.
' .
.~
.
''-, ~ ' , ` :
, 7~3~
SU~MARY AND DETAIL:ED DESCRIPTION OF T~IE INVENTION
This invention generally relates to compositions incorporating lecithin and hydrogen peroxide in an intimate admixture to provide a means to deliver topi-cal hydrogen peroxide in a stable form to a patient, . particularly as a treatment for acne. The major . strains of bacteria that cause acne and other patho-genic skin processes may be killed outright or effec-. tively inhibited in their growth by the application of i 10 a small quantity of hydrogen peroxide to the skin.
Accordingly, this invention provides an antibacterial composition comprising a mixture of lecithin and hydro-~ gen peroxide in a pharmaceutically acceptable solvent.
j The hydro~en peroxide concentration of this composition 15 ls 0.1-10% by weight, preferably about ~-8% by weight . of hydrogen peroxide based upon the total weight of ~he . composition. The total lecithin concentration is about 0.25~1S% by weight, preferably 1-2~, based upon the ~` total weight of the composition. The preferred solvent .~ 20 for compositions in accordance with this invention is .~ water. Since compositions in accordance with this invention are often used by consumers, suitable car-: riers, humectants, or emollients may be added to the composition to provide additional skin moisturization and other cosmetic effects. The compositions of this invention exhibit low toxicity.
This invention also includes the method of treat-~; ing acne by applying the composition of this invention, using water or other pharmaceutically acceptable solvents, to the skin of the patient.
Modifications and adaptations within the spirit ofthe invention disclosed herein will be apparent to , .
.
~7336~
persons skilled in the art from reading this specifi-cation and the claims appended here-to.
EXAMPLE I
Preparations in accordance with this inven-tion were evaluated in their action ln vitro against two common pathogens of the skin, S. aureus and P. acneus.
Filter paper discs 1.3 cm in diameter were saturated with a lecithin-hydrogen peroxide mixture in water and placed on petri dishes containiny cultures of the test bacteria on an agar-based medium. In each case the degree of bactericidal action was determined by measur-; ing the to-tal width o~ the zone of inhibition around the disc. Table I below sets forth results of these tests, the inhibition 20ne width figures excluding the diameter oE the test disc:
TABLE I
Lecithin H202 : Inhibition Zone Width (mm) (%) : (%) : S. aureus :: P. acneus
BEB-18~28 ~lec D. Keith LECITHIN-HYDROGEN PEROXID~ COMPOSITION
This invention relates generally to compositions incorporating lecithin and hydrogen peroxide in an intimate admixture to provide a means to deliver topi-cal hydrogen peroxide in a stable form to a patient.
The compositions according to this invention find particular value in treating acne~
_C GROUND OF THE INVENTION
Hydrogen peroxide has long been known for its potent disinfectant activity. However, the benefits of this activity are counterweighted by the instability (and resulting short shelf life) of aqueous hydrogen -~ peroxide. When any hydrogen peroxide preparation is placed on the skin, the hydrogen peroxide is immediate-ly in danger of decomposition by enzyme processes such as by catalase, which is present in human tissues and in a wide variety of bacteria. Furthermore, applica-tions of aqueous hydrogen peroxide rapidly lose their effectiveness because they run off the skin.
' .
.~
.
''-, ~ ' , ` :
, 7~3~
SU~MARY AND DETAIL:ED DESCRIPTION OF T~IE INVENTION
This invention generally relates to compositions incorporating lecithin and hydrogen peroxide in an intimate admixture to provide a means to deliver topi-cal hydrogen peroxide in a stable form to a patient, . particularly as a treatment for acne. The major . strains of bacteria that cause acne and other patho-genic skin processes may be killed outright or effec-. tively inhibited in their growth by the application of i 10 a small quantity of hydrogen peroxide to the skin.
Accordingly, this invention provides an antibacterial composition comprising a mixture of lecithin and hydro-~ gen peroxide in a pharmaceutically acceptable solvent.
j The hydro~en peroxide concentration of this composition 15 ls 0.1-10% by weight, preferably about ~-8% by weight . of hydrogen peroxide based upon the total weight of ~he . composition. The total lecithin concentration is about 0.25~1S% by weight, preferably 1-2~, based upon the ~` total weight of the composition. The preferred solvent .~ 20 for compositions in accordance with this invention is .~ water. Since compositions in accordance with this invention are often used by consumers, suitable car-: riers, humectants, or emollients may be added to the composition to provide additional skin moisturization and other cosmetic effects. The compositions of this invention exhibit low toxicity.
This invention also includes the method of treat-~; ing acne by applying the composition of this invention, using water or other pharmaceutically acceptable solvents, to the skin of the patient.
Modifications and adaptations within the spirit ofthe invention disclosed herein will be apparent to , .
.
~7336~
persons skilled in the art from reading this specifi-cation and the claims appended here-to.
EXAMPLE I
Preparations in accordance with this inven-tion were evaluated in their action ln vitro against two common pathogens of the skin, S. aureus and P. acneus.
Filter paper discs 1.3 cm in diameter were saturated with a lecithin-hydrogen peroxide mixture in water and placed on petri dishes containiny cultures of the test bacteria on an agar-based medium. In each case the degree of bactericidal action was determined by measur-; ing the to-tal width o~ the zone of inhibition around the disc. Table I below sets forth results of these tests, the inhibition 20ne width figures excluding the diameter oE the test disc:
TABLE I
Lecithin H202 : Inhibition Zone Width (mm) (%) : (%) : S. aureus :: P. acneus
2 0.5 10.6 17.3 2 0.5 11.6 12.4 1 1 12.0 13.6 1 1 12.9 16.9 2 1 11.5 14.9 2 1 12.7 14.A
4 1 11.5 17.3 4 1 13.7 1602 6 1 13.0 14.9 8 l 12.6 14.9 8 2 15.4 21.6 EXAMPLE II
In order to determine whether the lecithin inhi-bited or masked the therapeutic e~fect of the hydrogenperoxide in the test of Table I, aqueous hydrogen ....
; `
: .
~ J33~i4 ` (' peroxide was compared against ~ 4~ lecithin 1% hydrogen peroxide aqueous composition according to this inven-tion, formulated as set forth bel~w.
Soy Lecithin, Alcolec~L-100 4.0 (American Lecithin Co.) Triethanolamine 85%, USP 0.8 Glycerine 96~, USP 5.0 Mineral Oil, USP 8.0 Stearic Acid, USP 1.0 Ethylene Glycol Monostearate 1.0 Acetulated ~anolin Alcohol, 3.0 , Crodalan''LA (Croda) Glyceryl Monostearate 2.0 Dimethicone 1.0 ~5 Cetyl Alcohol 0~2 Imidazolidinyl Urea 0~5 Methylparaben 0.3 Propylpa~aben 0.2 Carbope 934 (B.F. Goodrich) 0.2 ~ Magnesium Aluminum Silicate 0.2 ; EDTA 0.02 10~ Hydrogen Peroxide 10.0 Purified Water, USP QS to 100 parts The data set forth below in Table II show that there is ~5 no meaningful difference in in vitro inhibition of S. aureus between 1% aqueous hydrogen peroxide and a : composition according to this invention containing the .same amount of hydrogen peroxide:
, ~ :
.'733~
TABLE II
Inhibition Zone Width (mm) Run_l Run 2 4% Lecithin 1% H2023.5
4 1 11.5 17.3 4 1 13.7 1602 6 1 13.0 14.9 8 l 12.6 14.9 8 2 15.4 21.6 EXAMPLE II
In order to determine whether the lecithin inhi-bited or masked the therapeutic e~fect of the hydrogenperoxide in the test of Table I, aqueous hydrogen ....
; `
: .
~ J33~i4 ` (' peroxide was compared against ~ 4~ lecithin 1% hydrogen peroxide aqueous composition according to this inven-tion, formulated as set forth bel~w.
Soy Lecithin, Alcolec~L-100 4.0 (American Lecithin Co.) Triethanolamine 85%, USP 0.8 Glycerine 96~, USP 5.0 Mineral Oil, USP 8.0 Stearic Acid, USP 1.0 Ethylene Glycol Monostearate 1.0 Acetulated ~anolin Alcohol, 3.0 , Crodalan''LA (Croda) Glyceryl Monostearate 2.0 Dimethicone 1.0 ~5 Cetyl Alcohol 0~2 Imidazolidinyl Urea 0~5 Methylparaben 0.3 Propylpa~aben 0.2 Carbope 934 (B.F. Goodrich) 0.2 ~ Magnesium Aluminum Silicate 0.2 ; EDTA 0.02 10~ Hydrogen Peroxide 10.0 Purified Water, USP QS to 100 parts The data set forth below in Table II show that there is ~5 no meaningful difference in in vitro inhibition of S. aureus between 1% aqueous hydrogen peroxide and a : composition according to this invention containing the .same amount of hydrogen peroxide:
, ~ :
.'733~
TABLE II
Inhibition Zone Width (mm) Run_l Run 2 4% Lecithin 1% H2023.5
3% H202 4.2 4.l 2 2 3.6 : 0.3% H202 2.7 *
0.1% H202 2.0 2.0 zero H20~
': lO * Test disc fell off when dish was turned.
; While the plaque tests set for-th above do not distin-guish between bactericidal and bacteriostatic action, this test method is considered to provide infoxmation of significance in predicting ln vivo activity.
;~ 15 EXAMPLE III
In addition to the compositions o~ Examples I and II, the following higher potency compositions have been found to be active using less lecithin:
~A) 7.5 Strength Hydrogen Peroxide 7.5~
Lecithin 0.375%
Deionized Water QS
(B) 5.0% Strength ~ Hydrogen Peroxide 5.0%
- 25 Lecithin 0.25%
Deioni~ed Water 05 :
,:
,~
., . . ~ . .
. ; ~ , ' ' ~ ~ .
.~ ,
0.1% H202 2.0 2.0 zero H20~
': lO * Test disc fell off when dish was turned.
; While the plaque tests set for-th above do not distin-guish between bactericidal and bacteriostatic action, this test method is considered to provide infoxmation of significance in predicting ln vivo activity.
;~ 15 EXAMPLE III
In addition to the compositions o~ Examples I and II, the following higher potency compositions have been found to be active using less lecithin:
~A) 7.5 Strength Hydrogen Peroxide 7.5~
Lecithin 0.375%
Deionized Water QS
(B) 5.0% Strength ~ Hydrogen Peroxide 5.0%
- 25 Lecithin 0.25%
Deioni~ed Water 05 :
,:
,~
., . . ~ . .
. ; ~ , ' ' ~ ~ .
.~ ,
Claims (5)
1. An antibacterial composition for the treatment of acne, comprising a mixture of about 0.25-15% by weight lecithin and about 0.1-10% by weight hydrogen peroxide in a pharmaceutically acceptable solvent, based on the total weight of the composition.
2. The composition of claim 1, wherein the H2O2 concentration is about 4-8% by weight.
3. The composition of claim 1, wherein the solvent is water.
4. The composition of claim 3, containing about 1% by weight lecithin.
5. The composition of claim 3, containing about 1-4%
by weight lecithin.
by weight lecithin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23027881A | 1981-01-30 | 1981-01-30 | |
| US230,278 | 1981-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1173364A true CA1173364A (en) | 1984-08-28 |
Family
ID=22864588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000394514A Expired CA1173364A (en) | 1981-01-30 | 1982-01-20 | Lecithin-hydrogen peroxide composition |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0057403A1 (en) |
| JP (1) | JPS57176911A (en) |
| AU (1) | AU7956482A (en) |
| CA (1) | CA1173364A (en) |
| DE (1) | DE3202347A1 (en) |
| FR (1) | FR2498932A1 (en) |
| GB (1) | GB2094623A (en) |
| IL (1) | IL64881A (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666893A (en) * | 1983-02-15 | 1987-05-19 | St. Thomas Institute | Methods of inducing resistance to bacterial and viral infections |
| JPH0635466B2 (en) * | 1988-09-28 | 1994-05-11 | 信越化学工業株式会社 | Method for producing diorganohalogenosilane |
| AU2003278775B2 (en) * | 2002-07-01 | 2010-06-17 | Maria Villani | Porifera-based therapeutic compositions for treating and preventing skin diseases |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1539771A (en) * | 1976-09-01 | 1979-02-07 | Quinoderm Ltd | Dermatological compositions |
-
1982
- 1982-01-15 AU AU79564/82A patent/AU7956482A/en not_active Abandoned
- 1982-01-20 CA CA000394514A patent/CA1173364A/en not_active Expired
- 1982-01-26 DE DE19823202347 patent/DE3202347A1/en not_active Withdrawn
- 1982-01-26 EP EP82100499A patent/EP0057403A1/en not_active Ceased
- 1982-01-27 GB GB8202289A patent/GB2094623A/en not_active Withdrawn
- 1982-01-28 IL IL64881A patent/IL64881A/en unknown
- 1982-01-28 FR FR8201328A patent/FR2498932A1/en active Pending
- 1982-01-29 JP JP57013172A patent/JPS57176911A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0057403A1 (en) | 1982-08-11 |
| GB2094623A (en) | 1982-09-22 |
| IL64881A (en) | 1984-10-31 |
| JPS57176911A (en) | 1982-10-30 |
| AU7956482A (en) | 1982-08-05 |
| IL64881A0 (en) | 1982-03-31 |
| FR2498932A1 (en) | 1982-08-06 |
| DE3202347A1 (en) | 1982-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4107328A (en) | Antimicrobial compositions and methods for utilizing the same employing mixtures of amines | |
| CA1045544A (en) | Inhibition of conditions arising from microbial production of ammonia | |
| US20090227523A1 (en) | Use of compatible solutes as substances having free radical scavenging properties | |
| MX9707512A (en) | Fast acting and persistent topical antiseptic. | |
| US5169630A (en) | External skin preparation | |
| DE69031497D1 (en) | INSULATION OF AMINOARGININE AND USE TO BLOCK THE FORMATION OF NITROGEN OXYDES IN THE BODY | |
| CA1252048A (en) | Stabilized clear benzoyl peroxide compositions | |
| JP2004504337A (en) | Cosmetic or dermatological preparations to prevent peroxide-induced skin damage | |
| US5916576A (en) | Method of scavenging free radicals using orange extract | |
| EP0686027B1 (en) | Verwendung eines phenolischen Diterpens zur Herstellung einer Zusammensetzung zur therapeutischen Verwendung auf der Haut | |
| JPH0892057A (en) | Cosmetic blended with extract of seed of coffee tree | |
| US5552158A (en) | Skin care composition | |
| GB1561475A (en) | Lastic acid composition | |
| JPS6236306A (en) | Skin-beautifying cosmetic | |
| JP2588031B2 (en) | Mouthwash containing tea polyphenol compound | |
| JPH09157153A (en) | Preparation for external use for skin | |
| JPH0826967A (en) | Cosmetic containing chlorogenic acid or its derivative | |
| CA1173364A (en) | Lecithin-hydrogen peroxide composition | |
| JPH03275613A (en) | Skin external agent | |
| JP4906179B2 (en) | Topical skin preparation | |
| KR930703252A (en) | Use of coucurbitin used in the manufacture of anti-allergic cosmetics or pharmaceutical, especially dermatological compositions, and methods of using the same | |
| US2542898A (en) | Peroxide liquid antiseptics | |
| KR100728443B1 (en) | Additive compositions including laminaria saccharina extract for cosmetics and cosmetics containing the same | |
| JPH0469122B2 (en) | ||
| JP2004002267A (en) | Collagenase inhibitor and its utilization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEC | Expiry (correction) | ||
| MKEX | Expiry |